Payment overview · 2025
General Payments
$23.59
1 reported records · 1 companies
Healthcare provider profile · identity verified
Thomas Ray Crow, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · WAURIKA, OK · NPI 1861436677
Verified facts
What the public records show
CMS Open Payments records show Thomas Ray Crow, M.D. received $23.59 in general payments during 2025 across 1 reported records.
Boston Scientific Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.59 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.59 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $23.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 458 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 62 |
| Alprazolam | Alprazolam | 210 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 39 |
| Lisinopril | Lisinopril | 151 | 39 |
| Potassium Chloride | Potassium Chloride | 126 | 33 |
| Metformin Hcl | Metformin Hcl | 123 | 30 |
| Gabapentin | Gabapentin | 120 | 29 |
| Furosemide | Furosemide | 119 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 23 |
| Celecoxib | Celecoxib | 109 | 24 |
| Omeprazole | Omeprazole | 106 | 35 |
| Eliquis | Apixaban | 102 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 17 |
| Jardiance | Empagliflozin | 100 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 26 |
| Losartan Potassium | Losartan Potassium | 92 | 24 |
| Meloxicam | Meloxicam | 90 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 12 |
| Diazepam | Diazepam | 79 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 11 |
| Clonazepam | Clonazepam | 67 | 11 |
| Allopurinol | Allopurinol | 66 | 13 |
| Glimepiride | Glimepiride | 65 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 13 |
| Carvedilol | Carvedilol | 59 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 21 |
| Donepezil Hcl | Donepezil Hcl | 56 | 15 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 19 |
| Estradiol | Estradiol | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 16 |
| Simvastatin | Simvastatin | 46 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 14 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Prednisone | Prednisone | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Famotidine | Famotidine | 30 | 13 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Cephalexin | Cephalexin | 28 | 19 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Nystatin | Nystatin | 28 | 11 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Risperidone | Risperidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.59 · 1 records | Boston Scientific Corporation | Varithena Administration Pack | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error